<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46601">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499575</url>
  </required_header>
  <id_info>
    <org_study_id>OH2-15-0005</org_study_id>
    <nct_id>NCT02499575</nct_id>
  </id_info>
  <brief_title>Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures</brief_title>
  <official_title>Exparel Pericapsular Injection: A Prospective Evaluation of Postoperative Pain in Bunion Surgery, First Metatarsophalangeal Joint Fusion, and Cheilectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OhioHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OhioHealth</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exparel is an FDA-approved local anesthetic (bupivacaine), in a long-release formulation. In
      this study the investigators plan to determine the ability of Exparel to control
      post-operative pain in common first metatarsophalangeal (MTP) joint procedures (bunion
      surgery, 1st MTP fusion, and cheilectomy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a prospective, randomized, single-blinded study of patients who
      are electing to undergo an outpatient first metatarsophalangeal (MTP) joint procedure
      (bunionectomy, 1st MTP fusion, or cheilectomy). As a standard, patients undergoing these
      procedures are given regional anesthesia (adductor canal block plus popliteal block).
      Patients are then given prescriptions for oral opioids to manage post-operative pain. The
      purpose of this study is to determine whether a single intrapopliteal administration of
      Exparel, in conjunction with the standard of care regional block, improves pain relief and
      therefore decreases use of post-operative opioids.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Logistical issues prevent efficient enrollment
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Use as Measured by Questionnaire</measure>
    <time_frame>Daily through the third day (72 hours) post-surgery</time_frame>
    <description>Compare time to first opioid use and total opioid use (reported as total morphine equivalents) over 72 hours between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Measured by Defense and Veterans Pain Scale</measure>
    <time_frame>Through 72 hours post-surgery (0, 6, 12, 24, 36, 48, 60, and 72 hours post-surgery)</time_frame>
    <description>Evaluate patient-reported pain scores (scale of 1-10) at 0, 6, 12, 24, 36, 48, 60, and 72 hours following surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Bunion</condition>
  <condition>Hallux Rigidus</condition>
  <arm_group>
    <arm_group_label>Regional Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional Block Plus Exparel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% ropivacaine</intervention_name>
    <description>Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine</description>
    <arm_group_label>Regional Block</arm_group_label>
    <arm_group_label>Regional Block Plus Exparel</arm_group_label>
    <other_name>ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)</description>
    <arm_group_label>Regional Block Plus Exparel</arm_group_label>
    <other_name>Liposomal bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18

          -  Undergoing distal or midshaft osteotomy for bunion correction, 1st MTP Fusion, or
             cheilectomy

        Exclusion Criteria:

          -  Age less than 18

          -  Unable to read/write English

          -  Dementia, history of dementia, or other significant mental impairment that would, in
             the opinion of the investigator, impede patient self-reporting

          -  Weight &lt;70 kg

          -  Allergy to local anesthetics

          -  History of long-acting opioid use or opioid tolerance (any patient receiving at least
             30 mg of oxycodone or equivalent per day (e.g., 6 tabs of Percocet 5/325 mg)
             regularly for approximately 7 days or more OR who require increased analgesic doses
             for a period long enough to develop tolerance to the effects of the opioid including
             analgesia and sedation)

          -  Any history of opioid misuse, illicit or prescription

          -  Prior MTP joint correction on the surgical limb

          -  Midfoot and hindfoot procedures performed concurrently, on the same day

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Hyer, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>OhioHealth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grant Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Foot and Ankle Center</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 25, 2016</lastchanged_date>
  <firstreceived_date>July 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exparel</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>Hallux valgus deformity</keyword>
  <keyword>bunionectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hallux Valgus</mesh_term>
    <mesh_term>Hallux Rigidus</mesh_term>
    <mesh_term>Hallux Limitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
